Vericel Corp (VCEL) stock

VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 15/30240% above fair value

$56.96−0.46 (-0.80%)

Close on Nov 13, 2026Market cap $2.92BP/E 96.5Yield –

Vericel price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Vericel's price to book ratio was 8.2× on Nov 11, 2026, against 6.3× a year earlier. Over the last 5 years it ranged from 4.6× to 11.7×, with a median of 7.7×.

Price to Book Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	8.2×	+2.6
2025	Dec 31, 2025	5.7×	−4.9
2024	Dec 31, 2024	10.5×	+2.2
2023	Dec 29, 2023	8.3×	+1.3
2022	Dec 30, 2022	7.0×	−4.7
2021	Dec 31, 2021	11.7×	−0.5
2020	Dec 31, 2020	12.2×	+4.2
2019	Dec 31, 2019	8.0×	+0.0
2018	Dec 31, 2018	8.0×	−3.4
2017	Dec 29, 2017	11.3×	+5.1
2016	Dec 30, 2016	6.3×	+3.9
2015	Dec 31, 2015	2.3×	+0.4
2014	Dec 31, 2014	1.9×	−0.9
2013	Dec 31, 2013	2.8×	−1.5
2012	Apr 30, 2012	4.3×	+1.2
2011	Dec 30, 2011	3.0×	−1.2
2010	Dec 31, 2010	4.3×	+1.6
2009	Dec 31, 2009	2.6×	–